Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

10053	Companies
205218	Keywords
135466	Articles
108808	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/11/2024 at 18:45, 1 year 8 months ago

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included

Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF

published on 07/03/2024 at 07:35, 1 year 8 months ago

Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project

Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 8 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 9 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 9 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 1 year 10 months ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF

published on 04/29/2024 at 18:25, 1 year 10 months ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE

published on 04/29/2024 at 18:20, 1 year 10 months ago

THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials

Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF

published on 04/29/2024 at 18:05, 1 year 10 months ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF

published on 04/26/2024 at 18:05, 1 year 10 months ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus

Accesswire

Published on 03/19/2026 at 07:30, 3 hours 39 minutes ago

Tocvan Drone Magnetic Data Strengthens Gold-Silver Targets Across Gran Pilar; Identifies Broad Zones for Expansion Potential
Published on 03/19/2026 at 06:35, 4 hours 34 minutes ago

Golden Lake Announces Securityholder Approval of Arrangement with McEwen Inc.
Published on 03/19/2026 at 01:05, 10 hours 4 minutes ago

Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 11 hours 24 minutes ago

Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 14 hours 9 minutes ago

PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie

View all ACCESSWIRE

EQS Group

Published on 03/19/2026 at 10:32, 37 minutes ago

Berentzen-Gruppe Aktiengesellschaft: JUMA Recharge+ – Berentzen Group launches functional lifestyle drink
Published on 03/19/2026 at 10:30, 39 minutes ago

Ulrike Brouzi takes over as Chairwoman of the Supervisory Board of Salzgitter AG
Published on 03/19/2026 at 10:14, 54 minutes ago

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
Published on 03/19/2026 at 10:05, 1 hour 3 minutes ago

Shipsy Launches AgentFleet, an AI Workforce for Logistics Operations
Published on 03/19/2026 at 10:05, 1 hour 4 minutes ago

Villeroy & Boch successfully holds its own in the 2025 financial year despite challenging market conditions

Les Echos

Published on 03/19/2026 at 08:45, 2 hours 24 minutes ago

Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 4 hours 9 minutes ago

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/19/2026 at 07:00, 4 hours 9 minutes ago

2025 Annual results and new strategic signature
Published on 03/18/2026 at 19:41, 15 hours 27 minutes ago

Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 17 hours 9 minutes ago

Deezer achieves profitability in FY25 as strategy delivers tangible results

View all LES ECHOS COMFI WIRE